Purepac to become Faulding through subsidiary consolidations.
Executive Summary
PUREPAC TO MERGE WITH FAULDING U.S. SUBSIDIARIES, CHANGE NAME to Faulding, Inc. in a series of transactions announced Aug. 10. Generic drug maker Purepac, which is 64%-owned by the Australian manufacturer Faulding, has agreed to acquire: Faulding Pharmaceuticals, which is Faulding's U.S. injectables marketing arm; Faulding Medical Devices, which is developing shell glass vial and device technologies; and Faulding Puerto Rico, which owns products and manufacturing facilities in Puerto Rico that formerly belonged to DuPont Merck.